Hims & Hers makes a big Europe push with an acquisition. Knockoff weight loss drugs could be nextByShannon CarrollPublishedJune 3, 2025
CVS and Express Scripts sued to block a new law restricting drug middlemenByBen KesslenPublishedMay 30, 2025
How Ozempic maker Novo Nordisk fell behind Eli Lilly in the weight loss drug raceByHarri WeberPublishedMay 30, 2025
New U.S. drug prices doubled amid a shift toward treating rare diseasesByKevin WilliamsPublishedMay 22, 2025
Noom is offering smaller doses of compounded Wegovy for weight lossByShannon CarrollPublishedMay 20, 2025
Novo Nordisk's CEO is out after the Ozempic maker's stock dropped 50% in a yearByCatherine BaabUpdatedMay 16, 2025
Trump's push for lower drug prices is just asking Big Pharma to make less moneyByKevin RyanPublishedMay 12, 2025
Eli Lilly's Zepbound beat Novo Nordisk’s Wegovy in a big weight loss drug studyByKevin RyanPublishedMay 12, 2025
Weight Watchers goes bankrupt even as it tries to ride the Ozempic boomByBen KesslenUpdatedMay 7, 2025
Trump says pharmaceutical tariffs are coming. Here's what to expectByShannon CarrollPublishedMay 6, 2025
Weight loss drugs can help employers cut health care costs, study saysByCatherine ArnstUpdatedApril 30, 2025
Hims & Hers strikes a deal with Novo Nordisk to sell Wegovy — and the stock soars 28%ByKevin RyanPublishedApril 29, 2025
Eli Lilly is stepping up its fight against copycat weight loss drugsByCatherine ArnstPublishedApril 23, 2025
Roche says it will invest $50 billion in the U.S. as tariff fears hit pharmaByCatherine ArnstPublishedApril 22, 2025
